Cleared Traditional

K182242 - VO200 – NeurOs Cerebral Oximetry System (FDA 510(k) Clearance)

Class II General & Plastic Surgery device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K182242 · Mespere Lifesciences, Inc. · General & Plastic Surgery device
Dec 2018
Decision
128d
Days
Class 2
Risk

K182242 is an FDA 510(k) clearance for the VO200 – NeurOs Cerebral Oximetry System. Classified as Cerebral Oximeter (product code QEM), Class II - Special Controls.

Submitted by Mespere Lifesciences, Inc. (Waterloo, CA). The FDA issued a Cleared decision on December 26, 2018 after a review of 128 days - within the typical 510(k) review window.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 870.2700 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General & Plastic Surgery review framework, consistent with the majority of Class II 510(k) submissions.

Submission Details

510(k) Number K182242 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 20, 2018
Decision Date December 26, 2018
Days to Decision 128 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF
Regulatory Context
Review time vs. panel average
4d faster than avg
Panel avg: 132d · This submission: 128d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code QEM Cerebral Oximeter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.2700
Definition Oximeter To Measure Cerebral Tissue Saturation
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General & Plastic Surgery devices follow this clearance model.